On March 15, there was some big news for one of Bio-Thera's major pipeline products. The phase I clinical trial for BAT1706
(a bevacizumab biosimilar), which is currently carrying out its global
development plan, has enrolled its first two healthy subjects in New
Zealand. This is the first clinical study of a bevacizumab biosimilar to
be conducted overseas by a Chinese company. At present, the clinical
study is proceeding as planned, with the phase I final report expected
to be completed in February 2017.
